-
Sector Analysis
Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015–2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting....
-
Sector Analysis
Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) is the fifth most common form of cancer and the fourth leading cause of cancer-related death worldwide, yet little is known about its exact etiology despite much ongoing research. Notably, G/GEJAC incidence rates are much higher in East Asia, particularly in Japan, China, and Korea. Approximately 90–95% of G/GEJACs are adenocarcinomas, while the rest represent rarer gastric malignancies, such as gastrointestinal stromal tumors, lymphomas, and neuroendocrine tumors. Historically, treatment of G/GEJAC has been mostly...
-
Sector Analysis
HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2028
Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). Historically HR+ breast cancer has typically been treated with hormone therapies which is the cornerstone of treatment for patients with this disease while...
-
Sector Analysis
Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2028
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90–95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80–95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC),...
-
Sector Analysis
Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030
Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain's neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients...
-
Sector Analysis
Chronic Myeloid Leukemia (CML): Global Drug Forecast and Market Analysis to 2030
The 8MM CML market was valued at $4.25 billion in 2020, and expects sales to peak in 2023, before falling at a CAGR of more than -3% during the period 2020-2030. The market growth will be driven by the launch or expansion of four agents, an increase in prevalent cases, and increased adoption of branded second and third-generation tyrosine kinase inhibitors (TKIs). Growth will be substantially inhibited by the patent expiries of all but one of the currently marketed TKIs...
-
Sector Analysis
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Pharmapoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin, Perjeta, and the tyrosine kinase inhibitor (TKI) Tykerb (lapatinib). During the forecast period from 2015–2025, GlobalData expects that the HER2-positive market will grow due to the launch of HER2-targeted agents in the early disease setting and...
-
Sector Analysis
Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027
Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs—Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide). The...
-
Sector Analysis
Ovarian Cancer - Opportunity Analysis and Forecasts to 2028
Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Primary cytoreductive debulking surgery and platinum based chemotherapy form the SOC in advanced ovarian cancer. Roche’s angiogenesis inhibitor Avastin (bevacizumab) is optionally...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.